No credit card. No commitment.
5000+ G2 reviews
OcuTerra Therapeutics
Research
Founded in 2011
Boston, MassachusettsOcuTerra Therapeutics
ResearchFounded in 2011Boston, Massachusetts
EmployeesOcuTerra Therapeutics' financial review
Employees
10
Total Funding
60.6M
Last Funding Round
25.6M
OcuTerra Therapeutics information
Non-Invasive, Transformational Approach to Treating Retinal Disease.OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity
OcuTerra Therapeutics industries
Research
Biotechnology research
OcuTerra Therapeutics' financial review
Employees
10
Total Funding
60.6M
Last Funding Round
25.6M
Employee Metrics
Technologies
Notable Alumni
Employees
Chief Financial Officer
Human Resources Consultant
Senior Advisor
Prospect on LinkedIn
Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download Extension
Why our clients choose Apollo
“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Erik Straub
Head of Product, Kickfurther
“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Michael Transon
CEO, Victorious
